OncLive TV

Justin T. Jordan, MD, MPH, FAAN, discusses treatment challenges and recent progress made with targeted therapies in adult NF1-associated PNs.

R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

Laura Huppert, MD, discusses ways that the frontline use of T-DXd in HER2-positive metastatic breast cancer may affect later-line treatment decisions.

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

Tahla Munir, MBChB, PhD, discusses the rationale for a MAIC of the phase 3 SEQUOIA and AMPLIFY trials in chronic lymphocytic leukemia.

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Jessica Paulus, ScD, discusses using real-world data to add an external control arm to a study of tucatinib plus liposomal doxorubicin in HER2+ breast cancer.

Marina Kremyanskaya, MD, PhD, details the mechanism of action of divesiran for the treatment of patients with polycythemia vera.

Alexey Danilov, MD, PhD, shares essential factors and unanswered questions regarding treatment sequencing in DLBCL.

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy and safety data from the PEACE study of radium-223 and enzalutamide in mCRPC.

Diva Baggio, MBBS, discusses findings from an international, multicenter study evaluating relapse patterns in patients with CNS relapse of LBCL.

Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.

Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.

Frank A. Sinicrope, MD, discuses the efficacy and safety of atezolizumab plus mFOLFOX6 in patients with stage III dMMR colon cancer

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Apar Kishor Ganti, MD, discusses the importance of molecular testing in NSCLC and the profiling capabilities of the Oncomine DX Express Test.

Darren Pan, MD, highlights the novelty of anito-cel in relapsed/refractory multiple myeloma, including the difference in safety profile vs cilta-cel.

Sonam Puri, MD, discusses future research directions and ongoing developments in small cell lung cancer.

Dickon Hayne, MD, FRCS, MBBS, discusses mitomycin in combination with BCG in patients with high-risk non–muscle-invasive bladder cancer.

Alexander Chehrazi-Raffle, MD, discusses findings from an exploratory analysis of the TiNivo-2 trial of tivozanib with/without nivolumab in metastatic RCC.

Ajai Chari, MD, expands on the evolving debate surrounding transplant eligibility determination in newly diagnosed multiple myeloma.

Alicia Morgans, MD, MPH, discusses how PRO data from the ARANOTE trial could inform the selection of darolutamide plus ADT for patients with mHSPC.

Ruby Arora, MD, discusses the design of a retrospective analysis of temporal trends in MCL incidence from 2000 to 2021.

Peter Voorhees, MD, details the clinical implications of cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Thomas Powles, MD, MBBS, MRCP, discusses the implications of data from sasanlimab plus BCG in patients with BCG-naive, high-risk NMIBC.

Naomi B. Haas, MD, discusses safety data from the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.